A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

Vaccine

Volumn 23, Issue 23, 2005, Pages 3076-3083

  Saul, Allan ^a,b,i   Lawrence, Greg ^a,b   Allworth, Anthony ^c   Elliott, Suzanne ^d   Anderson, Karen ^a,b   Rzepczyk, Christine ^a,b   Martin, Laura B ^a,b   Taylor, Darrin ^a,b   Eisen, Damon P ^c   Irving, David O ^e   Pye, David ^f   Crewther, Pauline E ^a,g   Hodder, Anthony N ^a,g   Murphy, Vincent J ^a,h   Anders, Robin F ^a,h  

^a The Cooperative Research Centre for Vaccine Technology   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d Genetic Solutions Pty Ltd   (Australia)

^e Biotechnology Australia   (Australia)

^f CSL LIMITED   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h LA TROBE UNIVERSITY   (Australia)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

AMA1; P. falciparum; Phase 1 vaccine trial

Indexed keywords

ACETYLSALICYLIC ACID; ADJUVANT; APICAL MEMBRANE ANTIGEN 1; MALARIA VACCINE; MONTANIDE ISA 720; PLACEBO;

ABSCESS; ADULT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EDEMA; ERYTHEMA; FACE EDEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LYMPHOCYTE ACTIVATION; MALARIA; MALE; MOUSE; NECROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALP; SEROCONVERSION; SIDE EFFECT; T LYMPHOCYTE;

EID: 20144388222     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.09.040     Document Type: Article

References (28)

1. J. Sachs, and P. Malaney The economic and social burden of malaria Nature 415 6872 2002 680 685
2. T.L. Richie, and A. Saul Progress and challenges for malaria vaccines Nature 415 6872 2002 694 701
3. C.H. Kocken, C. Withers-Martinez, and M.A. Dubbeld High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion Infect Immun 70 8 2002 4471 4476
4. M.C. Kennedy, J. Wang, and Y. Zhang In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response Infect Immun 70 12 2002 6948 6960
5. R.F. Anders, P.E. Crewther, and S. Edwards Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi Vaccine 16 2-3 1998 240 247
6. D.L. Narum, S.A. Ogun, A.W. Thomas, and A.A. Holder Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection Infect Immun 68 5 2000 2899 2906
7. P.E. Crewther, M.L. Matthew, R.H. Flegg, and R.F. Anders Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes Infect Immun 64 8 1996 3310 3317
8. W.E. Collins, D. Pye, and P.E. Crewther Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile Am J Trop Med Hyg 51 6 1994 711 719
9. A.W. Stowers, M.C. Kennedy, B.P. Keegan, A. Saul, C.A. Long, and L.H. Miller Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria Infect Immun 70 12 2002 6961 6967
10. O. Silvie, J.F. Franetich, and S. Charrin A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites J Biol Chem 2003
11. V.M. Marshall, M.G. Peterson, A.M. Lew, and D.J. Kemp Structure of the apical membrane antigen I (AMA-1) of Plasmodium chabaudi Mol Biochem Parasitol 37 2 1989 281 283
12. M.G. Peterson, V.M. Marshall, and J.A. Smythe Integral membrane protein located in the apical complex of Plasmodium falciparum Mol Cell Biol 9 7 1989 3151 3154
13. D.L. Narum, and A.W. Thomas Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites Mol Biochem Parasitol 67 1 1994 59 68
14. A.N. Hodder, P.E. Crewther, and M.L. Matthew The disulfide bond structure of Plasmodium apical membrane antigen-1 J Biol Chem 271 46 1996 29446 29452
15. V.M. Marshall, L. Zhang, R.F. Anders, and R.L. Coppel Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum Mol Biochem Parasitol 77 1 1996 109 113
16. S.D. Polley, and D.J. Conway Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene Genetics 158 4 2001 1505 1512
17. A.A. Escalante, H.M. Grebert, and S.C. Chaiyaroj Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project Mol Biochem Parasitol 113 2 2001 279 287
18. S.D. Polley, W. Chokejindachai, and D.J. Conway Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen Genetics 165 2 2003 555 561
19. A. Cortes, M. Mellombo, I. Mueller, A. Benet, J.C. Reeder, and R.F. Anders Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1 Infect Immun 71 3 2003 1416 1426
20. G.W. Lawrence, A. Saul, A.J. Giddy, R. Kemp, and D. Pye Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720 Vaccine 15 2 1997 176 178
21. A. Saul, G. Lawrence, and A. Smillie Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant Vaccine 1999 173145 173159
22. B. Genton, F. Al-Yaman, and R. Anders Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea Vaccine 18 23 2000 2504 2511
23. B. Genton, I. Betuela, and I. Felger A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea J Infect Dis 185 6 2002 820 827
24. C.H. Kocken, A.M. van-der-Wel, and M.A. Dubbeld Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization J Biol Chem 273 24 1998 15119 15124
25. A.P. Miles, H.A. McClellan, and K.M. Rausch Montanide ISA720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations Vaccine 23 19 2005 2530 2539
26. M. Nair, M.G. Hinds, and A.M. Coley Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1) J Mol Biol 322 4 2002 741 753
27. A.N. Hodder, P.E. Crewther, and R.F. Anders Specificity of the protective antibody response to apical membrane antigen 1 Infect Immun 69 5 2001 3286 3294
28. G. Lawrence, Q.Q. Cheng, and C. Reed Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers Vaccine 18 18 2000 1925 1931